Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

15.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

433
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
433
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Impact of platelet transfusion on outcomes in trauma patients.

Critical care (London, England)·2022
Same author

[How to manage anticoagulant treatment in case of invasive procedures (surgery, endoscopy…)].

Revue des maladies respiratoires·2019
Same author

[Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version].

Revue des maladies respiratoires·2019
Same author

[Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version].

Revue des maladies respiratoires·2019
Same author

User-friendly recommendations on antiplatelet agents: At last, a readable document.

Revista espanola de anestesiologia y reanimacion·2018
Same journal

Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Title of the study: Corrected Count Increment as a Predictor of Early Graft Dysfunction and Mortality Following Living Donor Liver Transplantation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

TLR4/MD-2 complex promotes transfusion-related acute lung injury pathogenesis through the activation of the AP-1 and NF-κB signaling pathways.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

The Strategic Utility of Cryopreserved Platelets in Outer Space.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Genotyping of Human Neutrophil Antigen-3 by High Resolution Melting Analysis in Southern Thai Blood Donors.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Transfusion rate and risk factors in hemiarthroplasty of hip: A nationwide cohort study.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K

[Antiplatelet agents and transfusion].

P Gaussem1, A-C Martin2, T Belleville-Rolland1

  • 1Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Inserm UMR-S1140, faculté de pharmacie, 75006 Paris, France.

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|June 25, 2017
PubMed
Summary
This summary is machine-generated.

Managing bleeding risks from antiplatelet agents requires tailored strategies. Platelet transfusions may not effectively reverse ticagrelor

Keywords:
AntidoteAntiplatelet agentsAspirineBleedingClopidogrelHémorragieMédicaments antiplaquettairesP2Y12Platelet transfusionPrasugrelTicagrelorTransfusion plaquettaire

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Antiplatelet agents increase bleeding risk, necessitating specific management strategies.
  • Platelet transfusion is a common but variably effective method for neutralizing antiplatelet effects.
  • The pharmacological properties of antiplatelet drugs influence the efficacy of reversal strategies.

Purpose of the Study:

  • To review the management of bleeding complications associated with antiplatelet agents.
  • To evaluate the effectiveness of platelet transfusion in neutralizing various antiplatelet drugs.
  • To discuss alternative therapeutic options for managing bleeding events.

Main Methods:

  • Literature review of studies on antiplatelet agents and bleeding management.
  • Analysis of the pharmacological mechanisms of action for different antiplatelet drugs.
  • Evaluation of evidence supporting platelet transfusion and other interventions.

Main Results:

  • Platelet transfusion can correct aspirin and clopidogrel inhibition but is ineffective for ticagrelor.
  • The clinical benefit of platelet transfusion is debated, with recent studies challenging its utility.
  • Perioperative use for high-risk surgery and severe hemorrhages remain indications for platelet transfusion.

Conclusions:

  • Management of antiplatelet-associated bleeding must be individualized based on the agent and clinical context.
  • Ticagrelor neutralization remains a challenge, with a potential antidote under development.
  • Alternative treatments like desmopressin, tranexamic acid, and activated factor VII should be considered.